指南与共识疼痛医学术前评估与围术期医学

美国国防部共识指南:现役军人疼痛管理的神经调控治疗

US Department of Defense consensus guidelines on neuromodulation for pain management in an active-duty military population from a tri-service, multispecialty working group.
指南 / 共识 · Reg Anesth Pain Med · 2026-05-29

该指南由美军疼痛管理高级领导人组成的三军多学科工作组制定,采用改良Delphi法和USPSTF证据分级,就现役军人慢性疼痛的神经调控治疗达成共识。指南选出8个问题并实现100%共识,明确了与民用人群不同的军事特定考虑,如指挥部参与决策、6个月有限勤务、植入装置不合格入伍等。

要点

  • 永久植入前需与军人所属指挥部共同决策,并需在试验前逐渐减停阿片类药物。
  • 现役军人因生活方式活跃可能较少需要肌肉(如多裂肌)神经刺激,若植入则需6个月有限勤务。
  • 植入神经刺激器不合格入伍,保留决定前应进行军事职业 specialty 测试。

核心结论

  • 神经调控可为部分军人提供变革性机会,使其在挑战性条件下维持表现。
  • 决定使用神经调控前需考虑成功可能性、军人处置(如医疗 board、退役)及军事职业特定要求。

研究设计与样本

  • 指南制定:2025年1月国防健康局疼痛管理临床支持服务验证需求并认可制定;由陆军、海军和空军疼痛管理高级领导人组成共识 panel。
  • 采用改良Delphi法,使用改良USPSTF证据分级指南;预设声明阈值>50%同意,推荐阈值>75%同意。

主要发现

  • 8个问题被选入指南制定,委员会成员达成100%共识。
  • 与民用人群的治疗推荐差异包括:永久植入前需与军人指挥部共同决策;现役军人可能较少需要肌肉(如多裂肌)神经刺激;若植入装置则需6个月有限勤务;植入神经刺激器不合格入伍,保留决定前推荐军事职业 specialty 测试;试验永久植入前应逐渐减停阿片类药物。
  • 委员会指出某些责任区域限制植入装置人员部署,同意军人在部署前应在模拟环境中测试,但证据不足以推荐治疗后>3个月无限制全勤以符合非限制全球部署资格。

关键数值与推荐

  • 共识阈值:声明需>50%同意,推荐需>75%同意。
  • 8个问题达成100%共识。
  • 若现役军人接受装置植入,应置于6个月有限勤务期以改善功能。

临床怎么用

  • 军事疼痛医师治疗现役军人慢性疼痛时,可参考本共识指南规范神经调控装置的使用。
  • 植入永久装置前需与军人指挥部联合决策,并在试验前逐渐减停阿片类药物。
  • 考虑军人处置(医疗 board、退役)及军事职业特定要求(如战斗、水下、飞行、电子安全区域、无支持服务的严峻环境)。

局限性

  • 证据不足以推荐军人在治疗后>3个月无限制全勤以符合非限制全球部署资格。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Military pain medicine physicians often treat Service Members with chronic pain with implantable neural stimulators in the spine and near peripheral nerves. These procedures are performed to improve readiness, restore function and deployability; however, there are no consensus practice guidelines on the use of these devices, which has led to inequities in their application and the disposition of patients who receive them.In January 2025, the Defense Health Agency Pain Management Clinical Support Service validated the need for consensus practice guidelines and endorsed their creation. Senior leaders in pain management from the Army, Navy and Air Force were assembled as part of the consensus panel. A small ad hoc steering committee drafted preliminary questions which were modified and approved by the committee-at-large. A modified Delphi approach was employed using modified US Preventive Services Task Force grading of evidence guidelines. Greater than 50% agreement among committee members was the predetermined threshold to declare a statement, but >75% agreement was necessary to affirm a recommendation.Eight questions were selected for guideline development with 100% consensus achieved by committee members. Differences between treatment recommendations for military (vs non-military) personnel include a joint decision process involving a Service Member's Command prior to implanting a permanent device intended to improve their suitability for continued service; active-duty Service Members may be less likely to require muscle (eg, multifidus) neurostimulation due to their active lifestyles, but if they do receive a device they should be placed on limited duty for a 6-month time period to allow for improved function; an implanted neurostimulator is disqualifying for induction into the military and military occupational specialty testing is recommended before retention decisions are made; and that opioid therapy be tapered prior to trialing a patient for a permanent implant. Although the committee noted that some areas of responsibility limit deployment for personnel with implanted devices and agreed that Service Members should be tested in simulated environments before deployment, we found insufficient evidence to recommend that Service Members serve at full duty for >3 months without restrictions after treatment to be eligible for non-restricted worldwide deployments.Neuromodulation can provide a transformative opportunity for some military personnel, enabling them to maintain performance in challenging conditions. Considerations that should be addressed before deciding on the use of neuromodulation include the likelihood of success, the disposition of the Service Member (eg, medical board, separation from service), and military occupation-specific requirements such as anticipated duty in combat, underwater, flight, electronically secure areas, and in austere environments without support services.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. McLean BC, Phillips CR, Wilson SM, et al. US Department of Defense consensus guidelines on neuromodulation for pain management in an active-duty military population from a tri-service, multispecialty working group. Reg Anesth Pain Med. 2026. PMID: 42215258. doi:10.1136/rapm-2026-107787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。